KRENSAVAGE ASSET MANAGEMENT LLC
Q3 2021 Form 13-F
NEW YORK, NEW YORK
CIK 0001609251
· CRD 168976
· SEC-registered investment adviser
$318.8M Reported Value Total
KRENSAVAGE ASSET MANAGEMENT, LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $314,669,759, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $393.8M gross asset value
Hedge Fund: $393.8M
Source: Form ADV filed 2026-03-25
Reported value
$318.8M
Quarter over quarter
+5.3%
Holdings
13
Top-10 concentration
97.6%
Key People
Form ADV owners & control persons
Michael Paul Krensavage
MANAGING MEMBER/CHIEF EXECUTIVE OFFICER
Paul Joseph Paolino
CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2021 13F record
Q3 2021 13F filing summary
| Period of report | September 30, 2021 |
|---|---|
| Filed | November 16, 2021 |
| Form | 13F-HR |
| Reported value | $318.8M |
| Positions | 13 |
| Change in reported value | +8.2% |
| New positions | 1 |
| Exited positions | 1 |
| Position turnover | 14.3% |
| Top-10 concentration | 97.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
18 | $263.2M |
|
Q1 2026 13F
Filed May 15, 2026
|
20 | $255.7M |
|
Q4 2025 13F
Filed Feb 18, 2026
|
18 | $283.1M |
|
Q3 2025 13F
Filed Nov 17, 2025
|
17 | $234.7M |
|
Q2 2025 13F
Filed Aug 15, 2025
|
15 | $188.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
14 | $180.9M |
|
Q4 2024 13F
Filed Feb 18, 2025
|
12 | $169.0M |
|
Q3 2024 13F
Filed Nov 15, 2024
|
13 | $178.5M |
|
Q2 2024 13F
Filed Aug 15, 2024
|
13 | $217.8M |
|
Q1 2024 13F
Filed May 15, 2024
|
12 | $225.5M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
12 | $281.9M |
|
Q3 2023 13F
Filed Nov 15, 2023
|
12 | $271.6M |
|
Q2 2023 13F
Filed Aug 11, 2023
|
12 | $315.6M |
|
Q1 2023 13F
Filed May 16, 2023
|
12 | $329.3M |
|
Q4 2022 13F
Filed Feb 15, 2023
|
12 | $323.6M |
|
Q3 2022 13F
Filed Nov 15, 2022
|
14 | $314.1M |
|
Q2 2022 13F
Filed Aug 16, 2022
|
14 | $302.5M |
|
Q1 2022 13F
Filed May 17, 2022
|
13 | $290.1M |
|
Q4 2021 13F
Filed Feb 15, 2022
|
10 | $288.3M |
|
Q3 2021 13F
Filed Nov 16, 2021
|
13 | $318.8M |
27 earlier quarters on file — choose one from the quarter menu above.
Top 13 holdings · Q3 2021
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ENTA ENANTA PHARMACEUTICALS INC | $53.2M | 16.69% |
| 2 | ALKS ALKERMES PLC | $44.5M | 13.95% |
| 3 | REGN REGENERON PHARMACEUTICALS | $44.3M | 13.89% |
| 4 | UTHR UNITED THERAPEUTICS CORP | $38.3M | 12.0% |
| 5 | TARO TARO PHARMACEUTICAL INDUS | $34.7M | 10.89% |
| 6 | MCK MCKESSON CORP | $32.8M | 10.29% |
| 7 | BIIB BIOGEN INC | $29.2M | 9.16% |
| 8 | EXEL EXELIXIS INC | $21.1M | 6.63% |
| 9 | SRGA SURGALIGN HOLDINGS INC | $6.9M | 2.17% |
| 10 | EGRX EAGLE PHARMACEUTICALS INC | $6.0M | 1.89% |
| 11 | IVCRQ INVACARE CORP | $4.2M | 1.33% |
| 12 | TVTX TRAVERE THERAPEUTICS INC | $3.3M | 1.04% |
| 13 | NXTC NEXTCURE INC | $208.0K | 0.07% |
Values as reported on the Q3 2021 Form 13F. Every position is in the holdings table below.